From bortezomib to other inhibitors of the proteasome and beyond

D Buac, M Shen, S Schmitt, F Rani Kona… - Current …, 2013 - ingentaconnect.com
The cancer drug discovery field has placed much emphasis on the identification of novel
and cancer-specific molecular targets. A rich source of such targets for the design of novel …

Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials

Z Huang, Y Wu, X Zhou, J Xu, W Zhu, Y Shu… - Future oncology, 2014 - Taylor & Francis
The ubiquitin–proteasome system is a major pathway for protein degradation, so that
proteasome is now considered as an important target for drug discovery. Bortezomib, the …

Programmed cell death pathways and current antitumor targets

ML Tan, JP Ooi, N Ismail, AIH Moad… - Pharmaceutical …, 2009 - Springer
Apoptosis and autophagic cell deaths are programmed cell deaths and they play essential
roles in cell survival, growth and development and tumorigenesis. The huge increase of …

[HTML][HTML] New advances in targeted gastric cancer treatment

DC Lazăr, S Tăban, M Cornianu, A Faur… - World journal of …, 2016 - ncbi.nlm.nih.gov
Despite a decrease in incidence over past decades, gastric cancer remains a major global
health problem. In the more recent period, survival has shown only minor improvement …

Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer

J Mullenders, R Bernards - Oncogene, 2009 - nature.com
A major impediment to the effective treatment of cancer is the molecular heterogeneity of the
disease, which is also reflected in an equally diverse pattern of clinical responses to therapy …

Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?

H Wong, T Yau - The oncologist, 2012 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to: Identify
the subset of advanced gastric cancer patients who might benefit from approved anti-HER2 …

Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types

X Ling, D Calinski, AA Chanan-Khan, M Zhou… - Journal of Experimental & …, 2010 - Springer
Background Survivin is known playing a role in drug resistance. However, its role in
bortezomib-mediated inhibition of growth and induction of apoptosis is unclear. There are …

HIPPO signaling-related signature for predicting prognosis and therapeutic response in gastric cancer

R Jiang, J Wang, J Liang, D Lin, Q Mao… - Frontiers in …, 2023 - frontiersin.org
Background: Gastric cancer (GC) is a multifactorial progressive disease with high mortality
and heterogeneous prognosis. Effective prognostic biomarkers for GC were critically …

Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive …

A Jatoi, NR Foster, JR Egner… - International …, 2010 - spandidos-publications.com
Whether elderly patients with metastatic esophageal, gastroesophageal, and gastric cancer
do as well with chemotherapy as their younger counterparts was investigated in this pooled …

A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

MA Shah, DG Power, HL Kindler, KD Holen… - Investigational new …, 2011 - Springer
Purpose The transcription factor nuclear factor-kB (NFkB) is implicated in gastric cancer
carcinogenesis and survival, and its inhibition by proteosome inhibition is associated with …